Hematopoietic Cells from Ube1L-Deficient Mice Exhibit Impaired Short-Term Reconstitution Capacity Under the Stress of Bone Marrow Transplantation

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 613-613
Author(s):  
Xiuli Cong ◽  
Ming Yan ◽  
Xiaoyan Yin

Abstract Following bone marrow transplantation, donor stem cells are recruited from their quiescent status to promote the rapid reconstitution of a depleted hematopoiesis system in recipients. This dynamic process is tightly regulated by a complex of internal and external signals. The proper proliferation and differentiation of hematopoietic stem cells (HSCs) are crucial for reconstitution of hematopoiesis in recipients with bone marrow ablation. Therefore, thoroughly understanding the complex regulation of HSCs during transplantation will be very helpful for future therapeutic applications. Type I interferons (IFNs) are induced in various types of cells by different stimuli. Protein modification by the ubiquitin like modifier ISG15 (ISGylation) is strongly induced by Type I IFNs. To understand whether Type I IFN signaling and protein ISGylation are important for the rapid reconstitution of the hematopoietic system upon depletion, we examined the expression levels of IFNs and protein ISGylation during transplantation. Our results showed a clear increase in Type I IFNs in the bone marrow cells of recipient mice at 4, 6, 8, and 10 days after transplantation, and obviously higher levels of protein ISGylation in different tissues at 2, 4, 6, and 8 days after transplantation. To further investigate the role of protein ISGylation in hematopoiesis, we examined the phenotypes of the Ube1L knockout mouse. Ube1L is a critical enzyme for protein ISG15 modification. Ube1L deficient cells do not have protein ISGylation upon IFN stimulation. Steady-state hematopoiesis was unperturbed in Ube1L −/− mice. In addition, Ube1L deficiency did not affect the colony-forming ability of progenitors in vitro. The in vivo colony-forming unit spleen (CFU-S) assay showed that the frequency of CFU-S12 was normal, however, the size of the colonies derived from Ube1L deficient cells were clearly reduced compared to wild-type cells. In transplant experiments, the homing capacity of Ube1L-deficient donor cells was not affected, however, at 3 weeks posttransplant, noncompetitive transplantation experiment revealed a 50% reduction in repopulation potential of Ube1L −/− bone marrow cells compared with Ube1L +/+ cells (p = 0.0015). A competitive transplantation experiment magnified and extended the Ube1L −/− phenotype showing that the Ube1L −/− cells had a significantly lower repopulating ability after 3 weeks (p = 0.0141), but less pronounced differences at 6 and 12 weeks. The lineage commitment of engrafted Ube1L-deficent cells was not affected. Further study showed that after transplantation in the multipotent progenitor (MPP) population, the absence of Ube1L resulted in fewer Ube1L −/− donor cells than Ube1L +/+ wild-type donor cells when compared to the competitors (p = 0.0367). These results indicate that in conditions that call for rapid proliferation, such as bone marrow transplantation, protein ISGylation appears to be critically involved in promoting and enhancing the proliferative response of short-term repopulation. This study will contribute to a thorough understanding of stem cell characteristics under transplantation, and may provide novel strategies to predict the potential risk factors related to ISGylation defects and enhance the success rate of HSC transplantation.

1982 ◽  
Vol 155 (3) ◽  
pp. 949-954 ◽  
Author(s):  
D A Vallera ◽  
R J Youle ◽  
D M Neville ◽  
J H Kersey

A new method has been devised to eliminate T cells from murine bone marrow grafts across major histocompatibility barriers and thus prevent graft-vs.-host disease (GVHD). The method utilizes a monoclonal antibody directed at the Thy-1.2 antigen but is complement independent. To make anti-Thy-1.2 toxic, the antibody is covalently linked to the toxin ricin. Ricin ordinarily binds, enters, and kills cells through receptors containing galactose. The hybrid protein, anti-Thy-1.2-ricin, can enter and kill cells via the Thy-1.2 receptor. In the presence of lactose the usual entry route for ricin is largely blocked and the hybrid is shown to be a highly selective reagent that is T cell specific in its inhibition of mitogen-stimulated splenocytes. We have used a model of severe and fatal GVHD where BALB/c splenocytes and bone marrow cells are given to irradiated C57BL/6 recipients. Over 90% of these mice die by day 70, exhibiting signs of GVHD. When donor cells are pretreated with 0.5 microgram/ml of anti-Thy-1.2-ricin plus 200 mM lactose before injection, 10 of 11 animals survive through day 70 without signs of GVHD. These studies demonstrate that ricin linked to monoclonal antibodies may have utility related to the prevention of GVHD in human bone marrow transplantation.


Blood ◽  
1990 ◽  
Vol 75 (1) ◽  
pp. 296-304 ◽  
Author(s):  
DC Roy ◽  
R Tantravahi ◽  
C Murray ◽  
K Dear ◽  
B Gorgone ◽  
...  

Mixed hematopoietic chimerism (MC) is a common finding after allogeneic bone marrow transplantation (BMT), but the natural history of this phenomenon remains unclear. To understand the evolution and the implications of this finding, we performed a prospective analysis of the development of mixed chimerism in 43 patients with hematologic malignancies who received bone marrow (BM) from human leukocyte antigen (HLA)-identical sibling donors. T-cell depletion in vitro with anti-T12 (CD6) monoclonal antibody and rabbit complement was used as the only method of graft-versus-host disease (GVHD) prophylaxis. Overall, MC was identified in peripheral blood (PB) and BM in 22 of 43 (51%) patients evaluated. MC was found by restriction fragment length polymorphism (RFLP) analysis in 21 of 40 (53%) patients, by cytogenetic analysis in 6 of 29 (21%) patients, and by red blood cell phenotyping in 4 of 9 (44%) patients. RFLP studies were performed at 0.5, 1, 3, 6, 9, and 12 months post-BMT and then every 6 months, and showed a high probability of developing MC in the first 6 months after BMT followed by stabilization after 12 months. Cytogenetic analysis was less sensitive in detecting MC. Once MC was detected after BMT, the percentage of recipient cells increased very slowly over more than 3 years of follow- up, and no patient reverted to complete donor hematopoiesis (CDH). Thus, recipient and donor cells remained in a relative state of equilibrium for prolonged periods that seemed to favor recipient cells over donor cells. Patient's disease, remission status, or intensity of the transplant preparative regimen did not influence the subsequent development of mixed chimerism. Early immunologic reconstitution was the only factor that correlated with the subsequent chimeric status of the patients. The percentage and absolute number of T3 (CD3) and T4 (CD4) positive cells at day 14 after BMT were significantly higher in the patients who maintained CDH but NK cell reconstitution was similar in both groups, suggesting that early reconstitution with T cells may play a role in preventing recovery of recipient cells after BMT. GVHD was also associated with maintenance of CDH, but the probability of relapse, survival, and disease-free survival was identical in patients with MC and CDH.


Blood ◽  
1987 ◽  
Vol 70 (6) ◽  
pp. 1966-1968 ◽  
Author(s):  
J Laver ◽  
SC Jhanwar ◽  
RJ O'Reilly ◽  
H Castro-Malaspina

Abstract The origin of marrow stromal cells post allogeneic bone marrow transplantation (BMT) was studied. Two groups of patients receiving HLA- identical marrow grafts from sex mismatched siblings were included in the study: the first group (eight patients) received conventional marrow grafts and the second group (ten patients) received stromal cell and T cell depleted grafts. All patients showed hematopoietic engraftment with donor cells. Marrow aspirates obtained from these patients were used to establish stromal layers in long-term marrow cultures (LTMC) for 4 to 6 weeks. In both groups, karyotype analysis of nonhematopoietic cultured stromal cells showed host origin even as late as day 760 posttransplantation. Immunofluorescence methods using monoclonal antibodies against components of fibroblasts, macrophages, and endothelial cells, showed that the composition of stromal layers was similar to those obtained from normal controls. Our data indicate that marrow stromal progenitors capable of proliferation are nontransplantable and do not originate from a hematopoietic-stromal common progenitor.


Blood ◽  
1999 ◽  
Vol 94 (10) ◽  
pp. 3432-3438 ◽  
Author(s):  
Manuela Battaglia ◽  
Marco Andreani ◽  
Marisa Manna ◽  
Sonia Nesci ◽  
Paola Tonucci ◽  
...  

Bone marrow transplantation (BMT) from an HLA-identical donor is an established therapy to cure homozygous β-thalassemia. Approximately 10% of thalassemic patients developed a persistent mixed chimerism (PMC) after BMT characterized by stable coexistence of host and donor cells in all hematopoietic compartments. Interestingly, in the erythrocytic lineage, close to normal levels of hemoglobin can be observed in the absence of complete donor engraftment. In the lymphocytic lineage, the striking feature is the coexistence of immune cells. This implies a state of tolerance or anergy, raising the issue of immunocompetence of the host. To understand the state of the T cells in PMC, repertoire analysis and functional studies were performed on cells from 3 ex-thalassemics. Repertoire analysis showed a profound skewing. This was due to an expansion of some T cells and not to a collapse of the repertoire, because phytohemagglutinin stimulation showed the presence of a complex repertoire. The immunocompetence of the chimeric immune systems was further established by showing responses to alloantigens and recall antigens in vitro. Both host and donor lymphocytes were observed in the cultures. These data suggest that the expanded T cells play a role in specific tolerance while allowing a normal immune status in these patients.


1988 ◽  
Vol 69 (4) ◽  
pp. 471-475 ◽  
Author(s):  
Francesco Frassoni ◽  
Mario Sessarego ◽  
Andrea Bacigalupo ◽  
Paolo Strada ◽  
Mario Repetto ◽  
...  

Blood ◽  
1997 ◽  
Vol 90 (2) ◽  
pp. 873-885 ◽  
Author(s):  
Margot Zöller ◽  
Annette Schmidt ◽  
Angela Denzel ◽  
Jürgen Moll

Abstract Constitutive expression of a rat CD44 variant isoform, rCD44v4-v7, on murine T cells accelerates immune responsiveness. Because prolonged immunodeficiency can be a major drawback in allogeneic bone marrow transplantation, we considered it of special interest to see whether repopulation of lethally irradiated syngeneic and allogeneic mice may be influenced by constitutive expression of the rCD44v4-v7 transgene. When lethally irradiated syngeneic and allogeneic mice were reconstituted with bone marrow cells (BMC) from rCD44v4-v7 transgenic (TG) or nontransgenic (NTG) mice, the former had a clear repopulation advantage: thymocytes expanded earlier after reconstitution and, as a consequence, higher numbers of lymphocytes were recovered from spleen and lymph nodes. Lymphocytes also displayed functional activity in advance to those from mice reconstituted with BMC from NTG mice. Most importantly, after the transfer of BMC from TG mice into an allogeneic host, the frequency of host-reactive T cells decreased rapidly. Apparently, this was due to accelerated induction of tolerance. Because these effects were counterregulated by an rCD44v6-specific antibody, it is likely that they could be attributed to the rCD44v4-v7 TG product. Thus, expression of a CD44 variant isoform at high levels facilitated reconstitution with allogeneic BMC by accelerated establishment of tolerance and the regaining of immunocompetence.


Blood ◽  
2001 ◽  
Vol 97 (5) ◽  
pp. 1227-1231 ◽  
Author(s):  
Edwin M. Horwitz ◽  
Darwin J. Prockop ◽  
Patricia L. Gordon ◽  
Winston W. K. Koo ◽  
Lorraine A. Fitzpatrick ◽  
...  

Preclinical models have shown that transplantation of marrow mesenchymal cells has the potential to correct inherited disorders of bone, cartilage, and muscle. The report describes clinical responses of the first children to undergo allogeneic bone marrow transplantation (BMT) for severe osteogenesis imperfecta (OI), a genetic disorder characterized by defective type I collagen, osteopenia, bone fragility, severe bony deformities, and growth retardation. Five children with severe OI were enrolled in a study of BMT from human leukocyte antigen (HLA)–compatible sibling donors. Linear growth, bone mineralization, and fracture rate were taken as measures of treatment response. The 3 children with documented donor osteoblast engraftment had a median 7.5-cm increase in body length (range, 6.5-8.0 cm) 6 months after transplantation compared with 1.25 cm (range, 1.0-1.5 cm) for age-matched control patients. These patients gained 21.0 to 65.3 g total body bone mineral content by 3 months after treatment or 45% to 77% of their baseline values. With extended follow-up, the patients' growth rates either slowed or reached a plateau phase. Bone mineral content continued to increase at a rate similar to that for weight-matched healthy children, even as growth rates declined. These results suggest that BMT from HLA-compatible donors may benefit children with severe OI. Further studies are needed to determine the full potential of this strategy.


Blood ◽  
1987 ◽  
Vol 70 (5) ◽  
pp. 1490-1494 ◽  
Author(s):  
RJ Jones ◽  
M Zuehlsdorf ◽  
SD Rowley ◽  
J Hilton ◽  
GW Santos ◽  
...  

Abstract We examined the effects of varying incubation conditions on the in vitro activity of 4-hydroperoxycyclophosphamide (4HC). 4HC activity against CFU-GM and against the K562 tumor cell line decreased with increasing the RBC concentration of the incubation mixture. Increasing the concentration of nucleated bone marrow cells in the incubation mixture also decreased the 4HC activity. Evaluation of 53 consecutive patients undergoing autologous bone marrow transplantation (BMT) revealed that the incubation RBC concentration during clinical purging showed a similar effect on CFU-GM recovery. Aldehyde dehydrogenase content of RBCs and nucleated marrow cells appears to be the cause of the inhibition of 4HC activity. Although there was no difference in individual CFU-GM sensitivity to 4HC among normals, previously treated patients undergoing autologous BMT showed significant variability in CFU-GM sensitivity to 4HC. The combined effects of incubation RBC concentration and individual patient 4HC sensitivity appear to account for most of the variability in CFU-GM recovery and speed of hematologic recovery after clinical purging with 4HC.


Sign in / Sign up

Export Citation Format

Share Document